The generic drug lobby is calling on CMS to require Medicare Part D plan sponsors provide an explanation and justification for when they choose not to cover new generic drugs or biosimilar products on their formularies and to mandate the formulary review and approval process ensure plan sponsors cover these lower-cost treatments at rates comparable to coverage in the commercial market, according to comments sent Monday (Jan. 27) on the agency’s proposed rule on contract year 2026 policy and technical...